{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '53.', 'Hedayati M, Haffner MC, Coulter JB et al. Androgen Deprivation Followed by Acute', 'Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing', 'Radiation. Clin Cancer Res 2016; 22: 3310-3319.', '54.', 'Nieschlag ES, Behre HM. Testosterone preparations for clinical use in males. In', 'Testosterone: Action, Deficiency, Substitution, 4 Edition. Cambridge, UK: Cambridge Univ.', 'Press 2012.', '55.', 'Schweizer MT, Wang H, Luber B et al. Bipolar Androgen Therapy for Men With', 'Androgen Ablation Naive Prostate Cancer: Results From the Phase II BATMAN Study.', 'Prostate 2016; 76: 1218-1226.', '56.', 'Teply BA, Wang H, Luber B et al. Bipolar androgen therapy (BAT) in men with', 'metastatic castration-resistan prostate cancer and progression on androgen receptor-directed', 'therapy: results from the post-enzalutamide cohort of a multi-cohort, open-label, phase 2 trial.', 'Lancet Oncology 2017 [in press].', '57.', 'Schweizer M, Montgomery R. Sequencing Therapies in Metastatic Castration', 'Resistant Prostate Cancer. In Balaji K (ed) Castration Resistant Prostate Cancer. Springer', 'Science 2015.', '58.', 'Morris MJ, Huang D, Kelly WK et al. Phase 1 trial of high-dose exogenous', 'testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009; 56:', '237-244.', '59.', 'Szmulewitz R, Mohile S, Posadas E et al. A randomized phase 1 study of testosterone', 'replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009; 56:', '97-103.', '60.', 'Teply BA, Kachhap S, Eisenberger MA, Denmeade SR. Extreme Response to High-', 'dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer. Eur Urol 2016.', '61.', 'Dantzer F, Schreiber V, Niedergang C et al. Involvement of poly(ADP-ribose)', 'polymerase in base excision repair. Biochimie 1999; 81: 69-75.', '62.', 'Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose)', 'polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.', 'Carcinogenesis 1999; 20: 199-203.', '63.', 'Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA', 'mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.', '64.', 'Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours', 'with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.', '65.', 'Lomonosov M, Anand S, Sangrithi M et al. Stabilization of stalled DNA replication', 'forks by the BRCA2 breast cancer susceptibility protein. Genes Dev 2003; 17: 3017-3022.', '66.', 'Arnaudeau C, Lundin C, Helleday T. DNA double-strand breaks associated with', 'replication forks are predominantly repaired by homologous recombination involving an', 'exchange mechanism in mammalian cells. J Mol Biol 2001; 307: 1235-1245.', '67.', 'Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and', 'XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol', 'Chem 2004; 279: 55117-55126.', '68.', 'Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose)', 'polymerase in oncology. Clin Cancer Res 2007; 13: 1383-1388.', \"69. Annunziata CM, O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel\", 'therapeutic target in cancer. Clin Cancer Res 2010; 16: 4517-4526.', '81 (93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '70.', 'Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in', 'tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.', '71.', 'Hay T, Matthews JR, Pietzka L et al. Poly(ADP-ribose) polymerase-1 inhibitor', 'treatment regresses autochthonous Brca2/p53-mutan mammary tumors in vivo and delays', 'tumor relapse in combination with carboplatin. Cancer Res 2009; 69: 3850-3855.', '72.', 'Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient', 'mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum', 'drugs. Proc Natl Acad Sci U S A 2008; 105: 17079-17084.', '73.', 'Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality:', 'clearing up the misunderstandings. Mol Oncol 2011; 5: 387-393.', '74.', 'Murai J, Huang SY, Das BB et al. Trapping of PARP1 and PARP2 by Clinical PARP', 'Inhibitors. Cancer Res 2012; 72: 5588-5599.', '75.', 'Donawho CK, Luo Y, Luo Y et al. ABT-888, an orally active poly(ADP-ribose)', 'polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin', 'Cancer Res 2007; 13: 2728-2737.', '76.', 'Delaney CA, Wang LZ, Kyle S et al. Potentiation of temozolomide and topotecan', 'growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase', 'inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000; 6: 2860-2867.', '77.', 'Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary', 'tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-3925.', '78.', 'Miknyoczki SJ, Jones-Bolin S, Pritchard S et al. Chemopotentiation of temozolomide,', 'irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol', 'Cancer Ther 2003; 2: 371-382.', '79.', \"D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in\", 'the regulation of nuclear functions. Biochem J 1999; 342 (Pt 2): 249-268.', '80.', 'Elstrodt F, Hollestelle A, Nagel JH et al. BRCA1 mutation analysis of 41 human breast', 'cancer cell lines reveals three new deleterious mutants. Cancer Res 2006; 66: 41-45.', '81.', 'Giannini G, Ristori E, Cerignoli F et al. Human MRE11 is inactivated in mismatch', 'repair-deficient cancers. EMBO Rep 2002; 3: 248-254.', '82.', 'Goggins M, Schutte M, Lu J et al. Germline BRCA2 gene mutations in patients with', 'apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56: 5360-5364.', '83.', \"Brown JS, O'Carrigan B, Jackson SP, Yap TA. Targeting DNA Repair in Cancer:\", 'Beyond PARP Inhibitors. Cancer Discov 2017; 7: 20-37.', '84.', 'Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:', '646-674.', '85.', 'Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology', '2010; 138: 2073-2087.e2073.', '86.', 'Mackay J, Szecsei CM. Genetic counselling for hereditary predisposition to ovarian', 'and breast cancer. Ann Oncol 2010; 21 Suppl 7: vii334-338.', '87.', 'Pritchard CC, Mateo J, Walsh MF et al. Inherited DNA-Repair Gene Mutations in', 'Men with Metastatic Prostate Cancer. N Engl J Med 2016; 375: 443-453.', '88.', 'Mateo J, Carreira S, Sandhu S et al. DNA-Repair Defects and Olaparib in Metastatic', 'Prostate Cancer. N Engl J Med 2015; 373: 1697-1708.', '89.', 'Rugo HS, Olopade OI, DeMichele A et al. Adaptive Randomization of Veliparib-', 'Carboplatin Treatment in Breast Cancer. N Engl J Med 2016; 375: 23-34.', '82(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}